Balaji Amines Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Solid quarter, measured tone: Revenue grew ~12% YoY to ₹403 cr with EBITDA margin expanding to 25%, but management enters FY27 with a "positive but measured outlook" given raw material volatility and project ramp-up timelines.
• The capex cycle is the story: Three new plants (DME, NMM, ACN) and a ₹750 cr specialty chemicals expansion are under execution, with commissioning staggered across FY27; the payoff depends on customer adoption of first-in-country products.
• DME is the nearest catalyst, but revenue is back-half loaded: The plant is fully constructed and commissioning now, yet actual booked revenues are likely only in H2 FY27 as customer sampling and transport approvals play out.
• Margins guided to normalize lower: Management targets sustainable EBITDA of 22–23%, down from this quarter's 25%, as raw material prices swing sharply and new plants carry teething costs.
• What to watch next quarter: DME commissioning progress and first customer trial outcomes, the trajectory of methanol and MEA input costs, and any clarity on antidumping duty status post-June.

The Capex Pipeline: What Is Being Built and When

• DME plant (Unit 4): Fully constructed, commissioning activities ongoing, expected to be commissioned during Q1 FY27; management has ordered ~100 cylinders of 500 kg each for customer sampling and applied for road transport permission, expected in a month.
• NMM project: 5,000 TPA capacity under execution, expected to be commissioned during FY27.
• ACN plant: Improved-process Acetonitrile plant under execution, expected to be commissioned during Q2 FY27.
• Unit-I brownfield: EDA-based value-added products (DETA, TETA, PIP, AEEA, AEP) expected to be commissioned during H1 FY27.
• Unit-II greenfield (Chincholi): Erection and installation in progress for HCN, NaCN, EDTA and EDTA-2Na; expected to be commissioned during Q4 FY27.
• Balaji Specialty Chemicals expansion: ~₹750 cr phased expansion for HCN, NaCN, EDTA, EDTA-2Na and other advanced chemical products; granted Mega Project status by Government of Maharashtra under PSI 2019.
• Why expand despite low utilization: Management argues new projects are new products (DME, ACN with improved technology), not capacity additions to existing lines; only 1–2 plants like DMF, butylamines and battery chemicals run at lower utilization, and the company is "gearing up for tomorrow's requirements."
• No import risk for DME: Being in gas form, management does not expect significant competition from outside the country.

D Ram Reddy: "Our current financial year maybe about 30% to 40%, we should be in a position to utilize because there will be some teething problems in the production even it's and also using the new product is being the first time in the country and also adjusting to the product also will take some time. By end of the year, we should reach to 50% to 60% capacity. And the coming years, it will go to 80% to 90%."

DME: The Nearest Growth Catalyst

• Target markets: Aerosol industry (already 40,000–50,000 tons using other gases) and commercial establishments (baking, bulb, ceramics) that currently depend on LPG or natural gas; management sees a "tremendous shortage of LPG" creating substitution demand.
• Pricing advantage: Government increased commercial cylinder prices by ~₹1,000 per cylinder, improving DME's relative economics as an LPG alternative.
• Revenue timing: Actual booked revenues likely only in the second half of FY27, after customer trials, transport approvals and initial teething issues are resolved.
• Utilization ramp: 30–40% utilization targeted in FY27, reaching 50–60% by year-end, and 80–90% in subsequent years.
• Margin visibility is low: Management declined to forecast DME margins, citing unpredictable raw material price swings.

D Ram Reddy: "Wherever the LPG is used there we can use this. Like, Aerosol market that itself is more than 40,000 tons to 50,000 tons currently using the other gases. So there, it is easy to target by giving this DME."

Raw Material Volatility and Margin Mechanics

• Geopolitical price shock: Some raw materials are now double or even 2.5–3 times regular prices due to the current geopolitical situation; some plants in the industry may have shut down.
• Procurement strategy shift: Management now buys in shorter quantities for shorter periods, monitoring prices every 3–4 days instead of buying for the entire month.
• EDA/DETA pricing churn: Prices changed 3–4 times in March and continue changing every 3–4 days; management must stay alert on both sales and procurement sides to maintain margins.
• Subsidiary margin distortion: Balaji Specialty Chemicals gross margins compressed because MEA prices rose almost 3x normal, but the subsidiary is running only 10–15 days a month due to modification activities, so current numbers are not representative; real figures visible only from Q3 onwards.
• Q4 margin bridge: EBITDA margin reached 25% vs 19% YoY and 18% QoQ, supported by better operating leverage, stable raw material conditions (pre-geopolitical spike), prudent inventory planning, improved cost efficiencies and favorable product mix.
• Sustainable margin guided lower: Management targets 22–23% EBITDA on total sales, implying the 25% print is above the sustainable range.

D Ram Reddy: "Even if I give you some numbers today, the price is going on this, that will not work for your calculation because there is a -- because of this current geopolitical situation, every 2 days, every 3 days, there's a change in the prices."

Volume and Revenue Outlook

• FY27 volume growth (consolidated): 10–15% volume growth expected for the current year.
• FY27-end volume target: Minimum 25–30% volume growth from current levels by end of FY27, driven by three new plants (ACN, DME, NMM) and battery industries expected to start and stabilize; management calls this a conservative number.
• FY28 revenue target: Management reiterated the ₹3,000 cr revenue target for FY28.
• Volume stability in Q4: Total sales volume reached 27,341 MT vs 25,871 MT in Q4 FY25, supported by consistent demand across pharmaceuticals, agrochemicals, solvents and other specialty chemical applications.
• March production disruption: Production was briefly impacted in March 2026 due to an external geopolitical situation; the company managed through prudent inventory planning and uninterrupted raw material availability.

D Ram Reddy: "Definitely, you have not heard fully. I said the situation goes like this. We will be definitely reaching INR3,000 crores in 2028."

Battery Chemicals and Other Verticals

• Battery chemicals unit status: Production has started but not for battery chemicals specifically; product is being supplied to agro and pharma sectors at 20–25% capacity; some customers bought 100–150 tons, made electrolyte and sold it outside India, saying Indian battery companies are not yet ready.
• Commercial orders received: Some customers have placed commercial orders of 100–150 tons.
• Utilization outlook: Management is hoping for better utilization and waiting for battery companies to start in full swing.
• Customer concentration risk: One large metformin customer accounts for ~15–20% of total outflow; management says the customer is still buying and does not know the source of backward-integration concerns raised by an analyst, suggesting the customer may have cost disadvantages versus buying from Balaji.
• Antidumping duty uncertainty: DMF case not yet applied; EDA case was at final stage but the government repelled many products making them duty-free due to the geopolitical situation; exemption orders valid up to end of June, with status known only after that.

Balance Sheet and Corporate Actions

• Zero-debt stand-alone: Balaji Amines continues to remain a zero-debt company on a stand-alone basis.
• Balaji Specialty Chemicals IPO: Too early to discuss; IPO postponed because the company wants all products in the market first before deciding on action.
• BSE stake increase: Both Boards and shareholders are involved; they will take appropriate time and decisions; management deflected further questioning.
• Investor plant visit: Management will invite investor stakeholders for a plant visit by this month or next month mid to witness expansions.

D Ram Reddy: "It's too early, Rajiv, to discuss. But why the IPO is postponed because, we want to come with the -- all the products into the market, then we will talk about the -- what action to be taken."

Guidance & Commitments

Key Metrics